AccuStem Sciences Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ACMSY research report →
Companywww.accustem.com
Accustem Sciences Limited engages in the genomic signature-based assay business for the prognosis of early and late recurrence of ER+/HER2 breast cancer in early stage breast cancer patients. The company was incorporated in 2020 and is based in London, the United Kingdom.
- IPO
- 2021
- HQ
- London, GB
Price Chart
Valuation
- Market Cap
- $0
- P/E
- -0.00
- P/S
- 0.00
- P/B
- -0.54
- EV/EBITDA
- 0.00
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 205.94%
- ROIC
- 45350.84%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-1,756,096,000 · -116584.12%
- EPS
- $-0.12 · 7.69%
- Op Income
- $-1,756,096,000
- FCF YoY
- -127957.90%
Performance & Tape
- 52W High
- $0.56
- 52W Low
- $0.01
- 50D MA
- $0.14
- 200D MA
- $0.23
- Beta
- 0.00
- Avg Volume
- 18.16K
Get TickerSpark's AI analysis on ACMSY
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 13, 25 | CERRONE GABRIELE M | buy | 400 |
| Jun 13, 25 | CERRONE GABRIELE M | buy | 2,000 |
| Jun 12, 25 | CERRONE GABRIELE M | buy | 8,991 |
| Jun 11, 25 | CERRONE GABRIELE M | buy | 28,205 |
| Apr 9, 25 | CERRONE GABRIELE M | buy | 3,000 |
| Apr 8, 25 | CERRONE GABRIELE M | buy | 35,000 |
| Apr 7, 25 | CERRONE GABRIELE M | buy | 35,000 |
| Apr 7, 25 | CERRONE GABRIELE M | buy | 17,802 |
| Mar 18, 25 | CERRONE GABRIELE M | buy | 100,000 |
| Dec 31, 24 | CERRONE GABRIELE M | buy | 100,000 |
Our ACMSY Coverage
We haven't published any research on ACMSY yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ACMSY Report →